Luke Miels

Money Moves

Leading GSK's push back into oncology

GSK agreed to pay $10.6 billion in cash for Nuvalent, a Cambridge, Massachusetts biotech with two lung cancer drugs awaiting U.S. approval. At $124 a share, the price is about 40% above where Nuvalent traded before the deal. It is GSK's biggest acquisition in more than a decade.

Updated Jun 9

Money Moves

Assumed role January 1, 2026

For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.

Updated May 22